U.S. market Closed. Opens in 15 hours 42 minutes

PFE | Pfizer Inc. Stock Overview

(Stock Exchange: NYSE)
Day's Range N/A - N/A
52 Week Range N/A - N/A
Beta 0.28
Implied Volatility 26.97%
IV Rank 13.94%
Day's Volume N/A
Average Volume N/A
Shares Outstanding N/A
Market Cap N/A
Sector Healthcare
Industry Drug Manufacturers - General
IPO Date 1972-06-01
Valuation
Profitability
Growth
Health
P/E Ratio N/A
Forward P/E Ratio 8.71
EPS N/A
1YR Price Target 32.00
Dividend Yield 7.37%
Dividend Per Share N/A
Dividend ExDate 2024-11-08
Dividend PayDate 2024-12-02
Employees 88,000
Country USA
Website PFE
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
PFE's peers: ABBV, AMGN, AZN, BIIB, BMY, GILD, JNJ, LLY, MRK, NVS, OGN
*Chart delayed
Analyzing fundamentals for PFE we got that it has average fundamentals where Valuation is considered to be significantly undervalued, Profitability is unacceptably poor, Growth is exceptionally good and Health is weak. For more detailed analysis please see PFE Fundamentals page.

Watching at PFE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PFE Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙